168 related articles for article (PubMed ID: 10831323)
1. A native soluble form of CTLA-4.
Oaks MK; Hallett KM; Penwell RT; Stauber EC; Warren SJ; Tector AJ
Cell Immunol; 2000 May; 201(2):144-53. PubMed ID: 10831323
[TBL] [Abstract][Full Text] [Related]
2. B70 antigen is a second ligand for CTLA-4 and CD28.
Azuma M; Ito D; Yagita H; Okumura K; Phillips JH; Lanier LL; Somoza C
Nature; 1993 Nov; 366(6450):76-9. PubMed ID: 7694153
[TBL] [Abstract][Full Text] [Related]
3. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
[TBL] [Abstract][Full Text] [Related]
4. Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule.
Chen C; Gault A; Shen L; Nabavi N
J Immunol; 1994 May; 152(10):4929-36. PubMed ID: 7513726
[TBL] [Abstract][Full Text] [Related]
5. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses.
Roy M; Aruffo A; Ledbetter J; Linsley P; Kehry M; Noelle R
Eur J Immunol; 1995 Feb; 25(2):596-603. PubMed ID: 7533092
[TBL] [Abstract][Full Text] [Related]
6. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.
Freeman GJ; Lombard DB; Gimmi CD; Brod SA; Lee K; Laning JC; Hafler DA; Dorf ME; Gray GS; Reiser H
J Immunol; 1992 Dec; 149(12):3795-801. PubMed ID: 1281186
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).
Morton PA; Fu XT; Stewart JA; Giacoletto KS; White SL; Leysath CE; Evans RJ; Shieh JJ; Karr RW
J Immunol; 1996 Feb; 156(3):1047-54. PubMed ID: 8557978
[TBL] [Abstract][Full Text] [Related]
8. Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides.
Nuttall SD; Rousch MJ; Irving RA; Hufton SE; Hoogenboom HR; Hudson PJ
Proteins; 1999 Aug; 36(2):217-27. PubMed ID: 10398368
[TBL] [Abstract][Full Text] [Related]
9. Refolding and characterization of recombinant human soluble CTLA-4 expressed in Escherichia coli.
Cox GN; Pratt D; Smith D; McDermott MJ; Vanderslice RW
Protein Expr Purif; 1999 Oct; 17(1):26-32. PubMed ID: 10497065
[TBL] [Abstract][Full Text] [Related]
10. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.
Kearney ER; Walunas TL; Karr RW; Morton PA; Loh DY; Bluestone JA; Jenkins MK
J Immunol; 1995 Aug; 155(3):1032-6. PubMed ID: 7543510
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location.
Harper K; Balzano C; Rouvier E; Mattéi MG; Luciani MF; Golstein P
J Immunol; 1991 Aug; 147(3):1037-44. PubMed ID: 1713603
[TBL] [Abstract][Full Text] [Related]
12. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor.
Freeman GJ; Cardoso AA; Boussiotis VA; Anumanthan A; Groves RW; Kupper TS; Clark EA; Nadler LM
J Immunol; 1998 Sep; 161(6):2708-15. PubMed ID: 9743327
[TBL] [Abstract][Full Text] [Related]
13. Embryonic stem cells and embryoid bodies express lymphocyte costimulatory molecules.
Ling V; Munroe RC; Murphy EA; Gray GS
Exp Cell Res; 1998 May; 241(1):55-65. PubMed ID: 9633513
[TBL] [Abstract][Full Text] [Related]
14. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells.
Magistrelli G; Jeannin P; Herbault N; Benoit De Coignac A; Gauchat JF; Bonnefoy JY; Delneste Y
Eur J Immunol; 1999 Nov; 29(11):3596-602. PubMed ID: 10556814
[TBL] [Abstract][Full Text] [Related]
15. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4.
Höllsberg P; Scholz C; Anderson DE; Greenfield EA; Kuchroo VK; Freeman GJ; Hafler DA
J Immunol; 1997 Nov; 159(10):4799-805. PubMed ID: 9366404
[TBL] [Abstract][Full Text] [Related]
16. Characterization of CTLA-4 structure and expression on human T cells.
Lindsten T; Lee KP; Harris ES; Petryniak B; Craighead N; Reynolds PJ; Lombard DB; Freeman GJ; Nadler LM; Gray GS
J Immunol; 1993 Oct; 151(7):3489-99. PubMed ID: 8397258
[TBL] [Abstract][Full Text] [Related]
17. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
18. The role of CTLA-4 in regulating Th2 differentiation.
Oosterwegel MA; Mandelbrot DA; Boyd SD; Lorsbach RB; Jarrett DY; Abbas AK; Sharpe AH
J Immunol; 1999 Sep; 163(5):2634-9. PubMed ID: 10453003
[TBL] [Abstract][Full Text] [Related]
19. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation.
Tao X; Constant S; Jorritsma P; Bottomly K
J Immunol; 1997 Dec; 159(12):5956-63. PubMed ID: 9550393
[TBL] [Abstract][Full Text] [Related]
20. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
